Maxim Group Upgrades Coherus Oncology (NASDAQ:CHRS) to "Buy"

Key Points

• Coherus Oncology (NASDAQ:CHRS) was upgraded from a "hold" to a "buy" rating by Maxim Group, with a price target set at $4.00, indicating a potential upside of 217.46% from its current price.
• In contrast, Wall Street Zen downgraded Coherus Oncology from a "hold" to a "sell" rating, reflecting differing analyst opinions on the stock's performance.
• Institutional investors have increased their positions in Coherus Oncology, with over 72.82% of the stock owned by institutional investors and hedge funds, highlighting significant investment interest.

Maxim Group upgraded shares of Coherus Oncology (NASDAQ:CHRS - Free Report) from a hold rating to a buy rating in a research report report published on Thursday, MarketBeat Ratings reports. Maxim Group currently has $4.00 price objective on the biotechnology company's stock.

Separately, Wall Street Zen cut Coherus Oncology from a "hold" rating to a "sell" rating in a report on Tuesday, May 20th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $4.51.

Coherus Oncology Price Performance

Shares of NASDAQ:CHRS traded down $0.03 during trading on Thursday, reaching $1.35. The stock had a trading volume of 736,143 shares, compared to its average volume of 1,656,537. The stock has a market capitalization of $156.33 million, a PE ratio of 0.86 and a beta of 0.88. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.44 and a quick ratio of 1.43. Coherus Oncology has a 52 week low of $0.66 and a 52 week high of $2.43. The business's 50-day moving average price is $0.99 and its 200 day moving average price is $0.93.

Institutional Trading of Coherus Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CHRS. International Assets Investment Management LLC purchased a new position in Coherus Oncology during the second quarter valued at $33,000. CWM LLC raised its stake in shares of Coherus Oncology by 96.6% during the 1st quarter. CWM LLC now owns 49,793 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 24,468 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Coherus Oncology by 97.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 30,847 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 15,214 shares in the last quarter. Cerity Partners LLC increased its stake in shares of Coherus Oncology by 84.0% in the first quarter. Cerity Partners LLC now owns 54,676 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 24,953 shares during the period. Finally, Corient Private Wealth LLC grew its position in Coherus Oncology by 20.0% during the second quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company's stock valued at $44,000 after buying an additional 10,000 shares during the period. 72.82% of the stock is owned by hedge funds and other institutional investors.

Coherus Oncology Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.